- Home
- PESI vs CRVS Comparison
PESI vs CRVS Comparison
Compare PESI & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PESI
- CRVS
- Stock Information
- Founded
- PESI 1990
- CRVS 2014
- Country
- PESI United States
- CRVS United States
- Employees
- PESI N/A
- CRVS N/A
- Industry
- PESI Environmental Services
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- PESI Industrials
- CRVS Health Care
- Exchange
- PESI Nasdaq
- CRVS Nasdaq
- Market Cap
- PESI 208.0M
- CRVS 305.4M
- IPO Year
- PESI 1992
- CRVS 2016
- Fundamental
- Price
- PESI $11.42
- CRVS $4.11
- Analyst Decision
- PESI
- CRVS Strong Buy
- Analyst Count
- PESI 0
- CRVS 4
- Target Price
- PESI N/A
- CRVS $15.00
- AVG Volume (30 Days)
- PESI 115.2K
- CRVS 1.1M
- Earning Date
- PESI 08-07-2025
- CRVS 08-05-2025
- Dividend Yield
- PESI N/A
- CRVS N/A
- EPS Growth
- PESI N/A
- CRVS N/A
- EPS
- PESI N/A
- CRVS N/A
- Revenue
- PESI $59,419,000.00
- CRVS N/A
- Revenue This Year
- PESI $23.71
- CRVS N/A
- Revenue Next Year
- PESI $86.33
- CRVS N/A
- P/E Ratio
- PESI N/A
- CRVS N/A
- Revenue Growth
- PESI N/A
- CRVS N/A
- 52 Week Low
- PESI $6.25
- CRVS $1.92
- 52 Week High
- PESI $16.25
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- PESI 72.26
- CRVS 53.94
- Support Level
- PESI $10.97
- CRVS $3.79
- Resistance Level
- PESI $11.34
- CRVS $4.31
- Average True Range (ATR)
- PESI 0.35
- CRVS 0.29
- MACD
- PESI 0.09
- CRVS 0.00
- Stochastic Oscillator
- PESI 90.77
- CRVS 72.64
About PESI Perma-Fix Environmental Services Inc.
Perma-Fix Environmental Services Inc is a provider of both nuclear services and the management of nuclear and mixed waste. The company operates through two segments: The treatment segment offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).